- 4.
Ghanima W, Atar D, Sandset PM. Nye perorale antikoagulasjonsmidler – en oversikt. Tidsskr Nor Legeforen 2013; 133: 1940 – 5. [PubMed]
- 5.
European Medicines Agency. Preparatomtale Pradaxa. www.ema.europa.eu/docs/no_NO/document_library/EPAR_-_Product_Information/human/000829/WC500041059.pdf (15.3.2016).
- 6.
European Medicines Agency. Preparatomtale Xarelto. www.ema.europa.eu/docs/no_NO/document_library/EPAR_-_Product_Information/human/000944/WC500057108.pdf (15.3.2016).
- 7.
European Medicines Agency. Preparatomtale Eliquis. www.ema.europa.eu/docs/no_NO/document_library/EPAR_-_Product_Information/human/002148/WC500107728.pdf (15.3.2016)
- 8.
Molden E. P-glykoprotein – en pumpe av betydning for legemiddelrespons. Tidsskr Nor Lægeforen 2004; 124: 2921 – 3. [PubMed]
- 9.
Reilly PA, Lehr T, Haertter S et al. The effect of dabigatran plasma concentrations and patient characteristics on the frequency of ischemic stroke and major bleeding in atrial fibrillation patients: the RE-LY Trial (Randomized Evaluation of Long-Term Anticoagulation Therapy). J Am Coll Cardiol 2014; 63: 321 – 8. [PubMed] [CrossRef]
- 12.
FDA. Clinical phamacology and biopharmaceutics review(s). Washington D.C.: The U.S. Food And Drug Administration, 2010. www.accessdata.fda.gov/drugsatfda_docs/nda/2011/022406Orig1s000ClinPharmR.pdf (15.3.2016).
- 13.
Center for drug evaluation and research. Clinical rewiev. Washington D.C.: The U.S. Food And Drug Administration, 2012. www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202155Orig1s000MedR.pdf (15.3.2016).
- 17.
Hov I, Bjartnes M, Slørdal L et al. Tas legemidler som foreskrevet? Tidsskr Nor Legeforen 2012; 132: 418 – 22. [PubMed]
- 18.
Informasjon om warfarin og de direkte virkende perorale antikoagulasjonsmidlene dabigatran, rivaroksaban og apixaban (IS-2050) Oslo: Helsedirektoratet, 2015. https://helsedirektoratet.no/publikasjoner/informasjon-om-warfarin-og-de-perorale-antikoagulasjonsmidlene-dabigatran-rivaroksaban-og-apixaban (15.3.2016).
- 20.
Cohen D. Dabigatran: how the drug company withheld important analyses. BMJ 2014; 349: g4670. [PubMed]
- 23.
Al-Aieshy F, Malmström RE, Antovic J et al. Clinical evaluation of laboratory methods to monitor exposure of rivaroxaban at trough and peak in patients with atrial fibrillation. Eur J Clin Pharmacol 2016; 72: 671 – 9. [PubMed]
- 24.
Dias JD, Norem K, Doorneweerd DD et al. Use of thromboelastography (TEG) for detection of new oral anticoagulants. Arch Pathol Lab Med 2015; 139: 665 – 73. [PubMed]
- 26.
Farmakologiportalen. Norsk portal for legemiddel- og rusmiddelanalyser. www.farmakologiportalen.no (8.8.2016).
()
Denne artikkelen ble publisert for mer enn 12 måneder siden, og vi har derfor stengt for nye kommentarer.